Polaris Partners
VC Fund
Boston, United States
Polaris Partners is a VC fund in Boston focused on Biotechnology and Health Care. Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
- Total investments:
- 490
- Last investment:
- Lead investor:
- 27%
- Fund size:
- $182M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Polaris Partners invests in
Stages Polaris Partners invests in
Countries Polaris Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $4.5M–$82M
- Series B
- $7M–$107M
- Series C
- $10M–$107M
Investment Focus
Industry
- Biotechnology 104 (21%)
- Health Care 102 (21%)
- Medical 52 (11%)
- Therapeutics 46 (9%)
- Software 41 (8%)
Stage
- Series B 116 (24%)
- Series A 106 (22%)
- Series C 75 (15%)
- Funding Round 45 (9%)
- Seed 29 (6%)
Country
- United States 227 (46%)
- Ireland 5 (1%)
- Singapore 4 (1%)
- United Kingdom 3 (1%)
- The Netherlands 2 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Isaac Ciechanover
Partner
|
Partner | Total investments: 2 | Find email | |
Sharif Vakili
Associate
|
Associate | Total investments: 1 | Find email | |
Alan Crane
Partner and Entrepreneur
|
Partner and Entrepreneur | Total investments: 19 | Find email | |
Alexandra Cantley
Partner
|
Partner | Total investments: 8 | Find email | |
Amir Nashat
Managing Partner
|
Managing Partner | Total investments: 29 | Find email | |
| See all 18 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tavo Biotherapeutics
|
Tavo Biotherapeutics is a biotech company that develops injection therapies for eye diseases. | $17M / Series A / Jun 02, 2026 | |
Crossbow Therapeutics
|
Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $77M / Series B / Mar 18, 2026 | |
Tropic Biosciences
|
At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. | $105M / Series C / Mar 12, 2026 | |
TRex Bio
|
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $50M / Jan 27, 2026 | |
EpiBiologics
|
EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $107M / Series B / Jan 08, 2026 | |
Sovato Health
|
Sovato Health provides surgical access through remote robotic surgeon options. | $41M / Series B / Nov 04, 2025 | |
Indomo
|
Indomo is a clinical-stage firm that aims to improve access to quality healthcare through novel device-enabled treatments. | $25M / Seed / Oct 29, 2025 | |
Zag Bio
|
Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. | $80M / Series A / Oct 28, 2025 | |
Cirrus Therapeutics
|
Cirrus Therapeutics is a Biotechnology Research firm diganosing and treating eye diseases affecting ocular immune system. | $11M / Seed / Aug 19, 2025 | |
Cohere Health
|
Cohere Health is a healthcare technology company, focused on improving the efficiency and effectiveness of healthcare delivery. Cohere Health aims to simplify the complexities of the healthcare system by leveraging technology to streamline processes, enhance communication, and ultimately improve patient outcomes. The company may provide solutionsto various stakeholders in the healthcare ecosystem, including patients, providers, and payers. | $90M / Series C / May 14, 2025 | |
| See all 490 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Polaris Partners invest in?
Polaris Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 490 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Polaris Partners's check size?
Polaris Partners typically joins rounds of $4.5M–$82M at Series A, $7M–$107M at Series B and $10M–$107M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Polaris Partners participates in.
How do I contact Polaris Partners?
Public channels for Polaris Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Polaris Partners?
The team at Polaris Partners includes Isaac Ciechanover (Partner), Sharif Vakili (Associate) and Alan Crane (Partner and Entrepreneur), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
